Full-Time
Director – Medical Affairs Training
Updated on 9/6/2024
Biopharmaceuticals for eye and infectious diseases
$191.2k - $267.8kAnnually
Senior, Expert
United States
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for other conditions, including Lyme Disease Prevention and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. The goal of Tarsus Pharmaceuticals is to provide effective medical treatments that improve patient outcomes in areas where there are currently few options.
Company Stage
IPO
Total Funding
$610.6M
Headquarters
Irvine, California
Founded
2017